Forrest D L, Thompson K, Nevill T J, Couban S, Fernandez L A V
The Bone Marrow Transplantation Program of Atlantic Canada, Division of Hematology, Department of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada.
Bone Marrow Transplant. 2002 Jun;29(12):973-8. doi: 10.1038/sj.bmt.1703573.
Between 1993 and 2000, 24 patients with follicular lymphoma underwent high-dose chemo/radiotherapy and allogeneic hematopoietic stem cell transplantation (HSCT). Median age was 44 years, median interval from diagnosis to HSCT was 24 months and the median number of prior lines of treatment was three. Donor source was HLA matched sibling (23) or matched unrelated donor (one). Conditioning therapy was busulfan based in 22 patients and included total body irradiation in two. All patients received i.v. cyclosporine A and short-course methotrexate for GVHD prophylaxis. Nineteen patients are alive, a median of 2.3 years post HSCT. Death occurred due to transplant complications in four patients and one patient died of a stroke 10 months post HSCT. No patients have relapsed. The overall and progression-free survival was 78% (95% CI 63-97). Allogeneic HSCT for patients with progressive follicular lymphoma is feasible and may result in prolonged disease-free survival.
1993年至2000年间，24例滤泡性淋巴瘤患者接受了大剂量化疗/放疗及异基因造血干细胞移植（HSCT）。中位年龄为44岁，从诊断到HSCT的中位间隔时间为24个月，既往治疗线数的中位数为3。供体来源为HLA匹配的同胞（23例）或匹配的无关供体（1例）。22例患者的预处理方案以白消安为主，2例患者的预处理方案包括全身照射。所有患者均接受静脉注射环孢素A和短疗程甲氨蝶呤预防移植物抗宿主病（GVHD）。19例患者存活，HSCT后中位时间为2.3年。4例患者因移植并发症死亡，1例患者在HSCT后10个月死于中风。无患者复发。总生存率和无进展生存率为78%（95%可信区间63-97）。对进展期滤泡性淋巴瘤患者进行异基因HSCT是可行的，可能会延长无病生存期。
